SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AutoImmune-AIMM
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Thomas Stewart who wrote (102)5/1/1997 5:37:00 PM
From: Mel Kaplan   of 298
 
T>S> Yes the treatment group received whole bovine myelin.
So, a whole variety of antigens, including MBP, PLP< and MOP's were in the material fed. All may induce experimental disease (EAE).
The prior experiments re the myelin approach were reported by the Brigham group as showing that (1) myelin feeding resulted in fewer attacks vs a placebo fed group, and (2) that T-cell lymphocytes from MS patients were sensitive to MBP and PLP and secreted TGF-B1
suppressor cytokine, which could interfere with inflammation in MS.
Why the negative results in the AIMM trial? I was informed in an AIMM call of the placebo effect, the Brigham study was based on only 15 patients, and the difference in results was beyond explanation
as yet. Mel
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News